Short-Term Psychodynamic Psychotherapy in Patients with “Male Depression” Syndrome, Hopelessness, and Suicide Risk: A Pilot Study by Angeletti, Gloria et al.
 
Short-Term Psychodynamic Psychotherapy in Patients with “Male
Depression” Syndrome, Hopelessness, and Suicide Risk: A Pilot
Study
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Angeletti, Gloria, Maurizio Pompili, Marco Innamorati, Chiara
Santucci, Valeria Savoja, Mark Goldblatt, and Paolo Girardi.
2013. Short-term psychodynamic psychotherapy in patients with
“male depression” syndrome, hopelessness, and suicide risk: a
pilot study. Depression Research and Treatment 2013:408983.
Published Version doi:10.1155/2013/408983
Accessed February 19, 2015 11:59:28 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10594430
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAHindawi Publishing Corporation
Depression Research and Treatment
Volume 2013, Article ID 408983, 5 pages
http://dx.doi.org/10.1155/2013/408983
Research Article
Short-Term PsychodynamicPsychotherapy in
Patients with “MaleDepression”Syndrome,Hopelessness, and
SuicideRisk:A Pilot Study
GloriaAngeletti,
1 MaurizioPompili,
2 MarcoInnamorati,
2 ChiaraSantucci,
1 ValeriaSavoja,
1
Mark Goldblatt,
3,4 and PaoloGirardi
1,2,5
1D e p a r t m e n to fN e u r o s c i e n c e s ,M e n t a lH e a l t ha n dS e n s o r yF u n c t i o n sa n dD e p a r t m e n to fP s y c h i a t r y ,S a n t ’ A n d r e aH o s p i t a l ,
Sapienza University of Rome, 00189 Rome, Italy
2Department of Neurosciences, Mental Health and Sensory Functions and Department of Psychiatry, Suicide Prevention Center,
Sant’Andrea Hospital, Sapienza University of Rome, 1035 Via di Grottarossa, 00189 Rome, Italy
3McLean Hospital, Belmont, MA, USA
4Department of Psychiatry, Harvard Medical School, Cambridge, MA 02138, USA
5V i l l aR o s aM e d i c a lR e s e a r c hC e n t r e ,V i t e r b o ,I t a l y
Correspondence should be addressed to Maurizio Pompili; maurizio.pompili@uniroma1.it
Received 20 October 2012; Revised 23 December 2012; Accepted 23 December 2012
Academic Editor: H. Grunze
Copyright © 2013 Gloria Angeletti et al.isisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objectives and Methods. is was an observational study of the eﬃcacy of short-term psychodynamic psychotherapy (STPP) in
a sample of 35 (30 women and 5 men) patients with moderate-to-severe “male depression” (Gotland Scale for Male Depression
(GSMD)≥13) comorbid with unipolar mood disorder (dysthymia and major depression) or anxiety disorder. Outcome measures
were GSMD and BHS (Beck Hopelessness Scale) score changes from baseline. Results.P a t i e n t sh a das t r o n gr e s p o n s et oS T P Po n
theGSMD(estimatedmeanscorechange(±SE) = −9.08±2.74;𝑃𝑃 𝑃0.0𝑃;partialetasquared = 0.50),butnotontheBHS(estimated
meanscorechange(±SE) = −0.92±𝑃.55;𝑃𝑃 = 0.57;partialetasquared = 0.03).BHSscorechangesweresigni�cantlyassociatedwith
GSMD score changes (Pearson’s 𝑟𝑟 = 0.5𝑟; 𝑃𝑃 𝑃0.00𝑃), even when controlling for the severity of hopelessness at the baseline (partial
𝑟𝑟 = 0.𝑟2; 𝑃𝑃 𝑃0.00𝑃). Conclusions. STPP proved to be eﬀective in patients suﬀering from “male depression” although hopelessness
was only marginally reduced by this treatment which points to the need to better understand how STPP can be involved in the
reduction of suicide risk.
1. Introduction
e term “depression” encompasses a wide range of condi-
tionsthatmayoccuralongacontinuum,rangingfrommilder
formsof discomfort to more severe and persistent form, as in
the case of major depression. Depression is the leading cause
of disability and the 4th leading contributor to the global
burden of disease [1, 2]a n db yt h ey e a r2 0 2 0 ,i ti sp r o j e c t e d
to become the 2nd leading contributor to the global burden
of disease in all ages and both sexes [1].
Major depression is the most frequent mental illness in
t h ew o r l d[ 3–6]. For example, in the US, the Epidemiological
Catchment Area (ECA) Study indicated a one-month preva-
lence between 1.7% and 3.4% [7], and more recently, the
NationalComorbiditySurveyReplication(NCS-R)estimated
a 12-month prevalence of 6.6% [8]. Nevertheless, prevalence
of moderate-to-severe depressive symptoms could be much
higher [9–11].
In 2010, the British National Institute for Health and
Clinical Excellence (NICE) commissioned the development
of an updated version of the guideline on the treatment
and management of depression in adults [12]. e NICE
guideline pointed out that people who suﬀer from depres-
sion usually prefer psychological treatments to medication2 Depression Research and Treatment
[13] and value outcomes beyond symptom reduction [14].
e NICE guideline indicated that it was not possible to
demonstrate a consistent picture of any clinically important
bene�tforshort-termpsychodynamicpsychotherapy(STPP)
in depression. While cognitive-behavioral therapy and inter-
personal therapy continue to have the most evidence for
eﬃcacy [15], however, some randomized trials and meta-
analyses indicated that STPP could be eﬀective in reducing
symptoms and in improving functional ability of patients
with mild or moderate depression [16–20].
Based on the experiences of the Gotland Study, Wålinder
and Rutz [21] identi�ed a male depressive syndrome includ-
ing low stress tolerance, acting-out behavior, poor impulse
control, substance abuse and family history of depression,
alcoholism, and suicidality. e authors also devised an
instrument to measure such syndrome, the Gotland Scale for
Male Depression [22]. Despite its name, male depression is
common in women; for example, female students showed a
greater risk of male depression than their male counterparts
i no n es t u d y[ 23]. Male depression was found to be equally
severeinmenandwomenwhohadmadeanonviolentsuicide
attempt [24]. Both men and women with substance abuse
have a higher probability of having male depression and
higher suicide risk than those without substance abuse [25].
To date, no psychological therapies have been assessed
for their eﬃcacy in the treatment of male depression. us,
the aim of this study was to assess the eﬃcacy of STPP in
reducing “male depression” symptoms comorbid with mood
disorders or anxiety disorders in an outpatient setting. Our
hypothesis is that STPP can be eﬀective in reducing male
depression. Furthermore, we hypothesize that the reduction
in male depression will be signi�cantly associated with a
reduction of hopelessness, a proxy of suicide risk.
2. Materials and Methods
2.1. Participants. is was an observational study of the
eﬃcacy of STPP in a sample of 35 consecutive (30 women
and 5 men) outpatients with moderate to severe “male
depression” (Gotland Scale for Male Depression (GSMD) ≥
13) comorbid with an unipolar mood disorder (dysthymia
and major depression) or an anxiety disorder. Patients were
admitted between January and June 2009 at the Department
of Psychiatry of the Sant’Andrea Hospital, Rome, Italy.
Inclusion criteria were the presence of moderate-to-severe
“male depression” syndrome as assessed by the GSMD, ages
between 18 and 64 years old, and a diagnosis of a mood
disorder or anxiety disorder. Exclusion criteria were the
presenceoflifetimediagnosisofdelirium,dementia,amnesic
orothercognitivedisorders,schizophreniaorotherpsychotic
disorders, anorexia nervosa and bulimia nervosa, comorbid
cluster B personality disorder, current presence of severe
suicide intent, a score on the Hamilton Depression Rating
Scale [26] of 28 or higher, and the inability to complete the
assessment for illiteracy or the denial of informed consent.
As concomitant psychotropic medication, only benzodi-
azepinesatamaximumof3mglorazepamequivalentperday
were allowed.
All the patients participated voluntarily in the study and
gave their informed consent. e study was approved by the
local IRB.
2.2. Measures. At intake the participants were assessed for
psychopathology by expert clinical psychologists through a
clinicalinterviewbasedontheDSM-IV-TR[27].epatients
werealsoadministeredtheGSMDandtheBeckHopelessness
Scale (BHS: [28]).
eGSMD[21,22,29]isascreeninginstrumentformale
depression, consisting of 13 items which are rated on a 4-
point Likert scale from 0 (not present) to 3 (present to a high
degree).Ascoreof12orlowerindicatesnodepression,scores
in the 13–26 range indicate moderate depression, and scores
>26 indicate severe depression [22]. e GMDS has good
validity [30–32].
e BHS is a 20-item scale for measuring the cognitive
componentofthesyndromeofdepression.isscaleassesses
threemajoraspectsofhopelessness:feelingsaboutthefuture,
loss of motivation, and expectations. Responding to the
20 true or false items on the Beck Hopelessness Scale,
individuals have to either endorse a pessimistic statement or
deny an optimistic statement. Research consistently supports
a positive relationship between BHS scores and measures of
depression, suicidal intent, and current suicidal ideation. In
addition, Beck et al. [33] carried out a prospective study of
1,958 outpatients and found that BHS scores were related
signi�cantly to eventual completed suicide. A cutoﬀ score
of 9 or above identi�ed 16 (94%) of the 17 patients who
eventually committed suicide. e high-risk group identi�ed
bythiscutoﬀscorewas11timesmorelikelytocommitsuicide
than the rest of the outpatients. e BHS may, therefore, be
used as an indicator of suicide potential. An Italian version
of the BHS has validated by the authors of the present study
[34, 35].
2.3. Interventions. Our intervention was derived from Mala-
n’s focused short-term technique [36, 37].
e treatment was administered in individual 45-minute
sessions per week for no longer than 40 sessions. STPP
explores those aspects of self not fully known, especially as
they are manifested and potentially in�uenced in the therapy
relationship [38]. It requires the psychological work to be
organized around a focus (i.e., a speci�c, strategic con�ictual
area to reach an understanding of the psychopathological
picture manifesting as a crisis), and that the therapist takes
an active role working through the central con�ictual area in
the psychic life of the patient.
e psychotherapists were psychologists or psychiatrists
certi�ed as psychotherapists from the Italian Board with a
previous training in STPP. Group supervision sessions were
carried out weekly allowing psychotherapists to discuss their
cases with senior psychotherapists/supervisor.
2.4. Analysis. e primary outcome measure was the mean
GSMD score changes from baseline.e secondary outcomeDepression Research and Treatment 3
T 1: Outcomes.
Variables
Estimated
diﬀerences
(M ± SE)
𝑃𝑃𝑃 Eﬀect size
(partial eta squared)
Men—% 14.3
Women—% 85.7
Age—M ± SD 40.00 ± 12.57
erapy duration—months 7.21 ± 2.03
Baseline BHS—M ± SD 10.53 ± 4.90 −0.92 ± 1.55 0.57 0.03
Follow-up BHS—M ± SD 9.03 ± 5.17
Baseline GMDS—M ± SD 23.57 ± 6.06 −9.08 ± 2.74 0.01 0.50
Follow-up GMDS—M ± SD 15.54 ± 8.89
Multivariate test of within subject eﬀect: Wilks’ 𝜆𝜆 𝜆 𝜆𝜆𝜆𝜆; 𝐹𝐹2;1𝜆 = 5.11; 𝑃𝑃 𝑃𝜆𝜆𝜆𝑃; 𝜂𝜂
2
𝑝𝑝 𝜆 𝜆𝜆𝑃1.
GMDS ≤ 13: no depression; GMDS between 13 and 26: moderate depression; GMDS > 26: severe depression. BHS ≤ 3: no hopelessness; BHS between 4 and
8: mild hopelessness; BHS ≥ 9 moderate-to-severe hopelessness.
wasm ea nsco r ec h a n g esfr o mbase lin eo nth eB HS.Res po n se
to treatment was assessed with a general linear model
for repeated measures. Diﬀerences between baseline and
followup are calculated on the estimated marginal means
(𝑀𝑀𝑒𝑒). Partial eta squared (𝜂𝜂
2
𝑝𝑝) are reported as measures of
eﬀect size. Associations between response on the GSMD and
on the BHS were assessed through Pearson’s 𝑟𝑟 and partial
indices of correlations. All the analyses were performed with
the statistical package for social sciences SPSS for Windows
19.0.
3. Results
e mean age of the patients was 40.0 years (SD 𝜆 12𝜆6;
Min./Max.: 20/62), 𝜆𝜆𝜆3 ± 1𝜆𝜆6 years for men and 𝜆𝜆𝜆𝜆 ± 12𝜆1
yearsforwomen.Sixtypercentofthepatientshadadiagnosis
ofanxietydisorders(mostly,generalizedanxiety,panicattack
disorder, and anxiety disorder not otherwise speci�ed), 26%
were diagnosed with dysthymia, and 14% were diagnosed
with a major depressive disorder.
Psychotherapysessionswerecarriedoutforameanof7.2
months (SD 𝜆 2𝜆𝜆; range, 5–10) (see Table 1). At baseline,
mean GSMD scores were 23.6 (SD 𝜆 6𝜆1; range, 14–37). Six-
ty-three percent of patients scored 9 or more on the BHS at
baseline (1𝜆𝜆𝑃 ± 𝜆𝜆𝜆).
Patients had a signi�cant strong response to the psycho-
dynamic psychotherapy on the GSMD (𝑀𝑀𝑒𝑒 ± SE 𝜆 −𝜆𝜆𝜆8 ±
2𝜆7𝜆; 𝑃𝑃 𝑃𝜆𝜆𝜆1; 𝜂𝜂
2
𝑝𝑝 𝜆 𝜆𝜆𝑃𝜆) ,b u tn o to nt h eB H S( 𝑀𝑀𝑒𝑒 ± SE 𝜆
−𝜆𝜆𝜆2±1𝜆𝑃𝑃;𝑃𝑃 𝜆 𝜆𝜆𝑃7;𝜂𝜂
2
𝑝𝑝 𝜆 𝜆𝜆𝜆3).Meanchangesonoutcome
measures were neither associated with the length of the
treatments (Pearson’s 𝑟𝑟 from −0.06 to 0.16), nor with the
baselineseverityofmaledepression(Pearson’s𝑟𝑟between0.05
and 0.07), or hopelessness (Pearson’s 𝑟𝑟 𝜆 𝜆𝜆𝜆𝑃). Only mean
BHS score change was moderately associated with baseline
severity of hopelessness (𝑟𝑟 𝜆 𝜆𝜆𝑃𝜆; 𝑃𝑃 𝑃𝜆𝜆𝜆1).
Furthermore,meanGSMDscorechangewassigni�cantly
associated with BHS score change (Pearson’s 𝑟𝑟 𝜆 𝜆𝜆𝑃6; 𝑃𝑃𝑃
𝜆𝜆𝜆𝜆1),evenwhencontrollingfortheseverityofhopelessness
at the baseline (partial 𝑟𝑟 𝜆 𝜆𝜆62; 𝑃𝑃 𝑃𝜆𝜆𝜆𝜆1).
4. Discussion
e results of this pilot study of short-term psychodynamic
psychotherapy for “male depression” are mixed. We found
that self-ratings of depressive symptoms were signi�cantly
improved, suggesting that this therapy is eﬀective for depres-
sive symptoms in these patients.
Self-ratings associated with increased suicide risk were
not signi�cantly aﬀected over the course of treatment. Even
those patients who reported a signi�cant response on the
MINI-basedsuicidalriskaertreatmentshowednoimprove-
ment on the BHS. is result is consistent with other studies,
s u c ha st h a to fL i n e h a ne ta l .[ 39], which showed a reduction
in the risk of suicide aer a psychotherapeutic intervention,
but no signi�cant changes between baseline and posttreat-
ment in BHS scores. However, cognitive behavioural therapy
proved to be superior in the reduction of hopelessness
(a proxy of suicide risk) compared to other therapeutic
interventions [40].
Although suicide risk has most oen been studied in
the context of depressive symptoms, it remains unclear what
distinguishes those depressions with lethal outcome from
those in which the patients do not attack themselves.
It should also be noted that these treatments took place
in a public psychiatric setting where their sessions are part of
thegovernmentsupportedpublichealthsystem,andpatients
paid a small additional fee. While there are diﬀerences
between sessions taking place in a therapist’s oﬃce and those
intheroomsofanoutpatientclinic(duetochangesintheset-
tingfromtimetotime,hospitalfurniture,whitecoatsaround,
etc.), every eﬀort was made to maintain standard procedures
andprovideagoodtestofSTPP.Nevertheless,wemustadmit
that discussion over the delivery of such psychotherapy in
public environment was oen raised nationwide, pointing to
caution in the generalization of our results.
Such important considerations may explain de�cits in
outcomes as compared with modalities in which STPP is
currently practiced.
It should also be noted that our original model was
derived from Malan’s technique; our approach shared prin-
ciples with Davanloo’s method [41, 42]. Although it is4 Depression Research and Treatment
generally acknowledged that Malan espoused the methods
of Davanloo, seeing in them a radical ful�lment of his own
work, recent eminent evidence also support a valid role
for Malan’s approach. Malan’s proposals, both in direct or
modi�ed forms, have been thoroughly tested in eﬃcacy
studies [43]. Moreover, common principles among short-
term psychotherapies can be identi�ed, which points to the
fact that Malan and Davanloo’s approaches have similarities
that are nowadays acknowledged among experts [44].
is study has noteworthy limitations, including mod-
erate sample size and treatment duration, mix of diagnoses,
nonrandomized and largely uncontrolled treatment regi-
mens, including use of benzodiazepine—all of which may
limit generalization of �ndings. However, all subjects were
selected for having speci�c features of depression and suicide
risk so that the sample was overall homogeneous. Despite
the fact that all psychotherapists involved in this study were
trained under the principles of the brief psychodynamic psy-
chotherapy [45], treatment bias might have been appeared,
even though all the therapists were routinely supervised
by senior psychotherapists. Although all psychotherapists
took careful notes and reported detailed description of each
session, there was no videotape or audiotape. No doubt,
this constitutes a limitation, however, concordant with the
limited facilities provided by the public service.
5. Conclusions
is study of the use of short-term psychodynamic therapy
for “male depression” with features of suicidality reveals how
diﬃcult it is to clearly address the suicide risk factors in such
patients. Although depressive symptoms appear to improve
relatively soon aer initiating therapy, suicidality lingers for
a much longer time. Further research is needed to clarify the
positive eﬀects of such therapy and the interaction between
depression and suicidality. Further studies are also needed
to distinguish what kinds of therapies are useful in rapidly
addressing suicide risk.
Authors’Contribution
All authors have made substantial contributions to concep-
tion and design or acquisition of data or analysis and inter-
pretation of data, have been involved in draing the paper
or revising it critically for important intellectual content, and
have given �nal approval of the version to be published.
Con�ictof �nterests
e authors declare that they have no con�ict of interests for
this research.
References
[1] World Health Organisation, Depression. What is depres-
sion?, World Health Organisation, Geneva, Switzerland, 2011,
http://www.who.int /mental_health/management/depression/
depression/de�nition/en/.
[2] T. B. Üstün, J. L. Ayuso-Mateos, S. Chatterji, C. Mathers, and C.
J. L. Murray, “Global burden of depressive disorders in the year
2000,”  eB r i t i s hJ o u r n a lo fP s y c h i a t r y , vol. 184, pp. 386–392,
2004.
[3] D. S. Hasin, R. D. Goodwin, F. S. Stinson, and B. F. Grant,
“Epidemiology of major depressive disorder: results from the
National Epidemiologic Survey on Alcoholism and Related
Conditions,” Archives of General Psychiatry, vol. 62, no. 10, pp.
1097–1106, 2005.
[4] C. Blanco, M. Okuda, J. C. Markowitz, S. M. Liu, B. F. Grant,
andD.S.Hasin,“eepidemiologyofchronicmajordepressive
disorder and dysthymic disorder: results from the National
EpidemiologicSurveyonAlcoholandRelatedConditions,”e
Journal of Clinical Psychiatry, vol. 71, no. 12, pp. 1645–1656,
2010.
[5] V. Lehtinen and M. Joukamaa, “Epidemiology of depression:
prevalence, risk factors and treatment situation,” Acta Psychi-
atrica Scandinavica, vol. 377, pp. 7–10, 1994.
[6] M. M. Ohayon, “Epidemiology of depression and its treatment
in the general population,” Journal of Psychiatric Research, vol.
41, no. 3-4, pp. 207–213, 2007.
[7] D. A. Regier, J. H. Boyd, J. D. Burke Jr. et al., “One-month
prevalence of mental disorders in the United States, based on
�ve epidemiologic catchment area sites,” Archives of General
Psychiatry, vol. 45, no. 11, pp. 977–986, 1988.
[8] R. C. Kessler, P. Berglund, O. Demler et al., “e epidemiology
of major depressive disorder: results from the National Comor-
biditySurveyReplication(NCS-R),”eJournaloftheAmerican
Medical Association, vol. 289, no. 23, pp. 3095–3105, 2003.
[9] J. L. Rushton, M. Forcier, and R. M. Schectman, “Epidemiology
of depressive symptoms in the National Longitudinal Study of
Adolescent Health,” Journal of the American Academy of Child
and Adolescent Psychiatry, vol. 41, no. 2, pp. 199–205, 2002.
[10] D. Blazer, D. C. Hughes, and L. K. George, “e epidemiology
of depression in an elderly community population,” e Geron-
tologist, vol. 27, no. 3, pp. 281–287, 1987.
[11] S. Win, K. Parakh, C. M. Eze-Nliam, J. S. Gottdiener, W. J.
Kop, and R. C. Ziegelstein, “Depressive symptoms, physical
inactivity and risk of cardiovascular mortality in older adults:
the Cardiovascular Health Study,” Heart, vol. 97, no. 6, pp.
500–505, 2011.
[12] National Collaborating Centre for Mental Health, Depression.
e NICE Guideline on the Treatment and Management of
Depression in Adults, e British Psychological Society & e
Royal College of Psychiatrists, London, UK, 2010.
[13] M. A. Prins, P. F. M. Verhaak, J. M. Bensing, and K. van der
Meer,“Healthbeliefsandperceivedneedformentalhealthcare
of anxiety and depression—the patients’ perspective explored,”
Clinical Psychology Review, vol. 28, no. 6, pp. 1038–1058, 2008.
[14] M.Zimmerman,I.Chelminski,J.B.McGlinchey,andD.Young,
“Diagnosing major depressive disorder X: can the utility of
the DSM-IV symptom criteria be improved?” e Journal of
NervousandMentalDisease,vol.194,no.12,pp.893–897,2006.
[15] S. V. Parikh, Z. V. Segal, S. Grigoriadis et al., “Canadian Net-
work for Mood and Anxiety Treatments (CANMAT) clinical
guidelines for the management of major depressive disorder
in adults. II. Psychotherapy alone or in combination with
antidepressant medication,” Journal of Aﬀective Disorders, vol.
117, supplement 1, pp. S15–S25, 2009.
[16] J. K. Salminen, H. Karlsson, J. Hietala et al., “Short-term psy-
chodynamic psychotherapy and �uoxetine in major depressiveDepression Research and Treatment 5
disorder: a randomized comparative study,” Psychotherapy and
Psychosomatics, vol. 77, no. 6, pp. 351–357, 2008.
[17] E. Driessen, P. Cuijpers, S. C. M. de Maat, A. A. Abbass, F.
de Jonghe, and J. J. M. Dekker, “e eﬃcacy of short-term
psychodynamicpsychotherapyfordepression:ameta-analysis,”
Clinical Psychology Review, vol. 30, no. 1, pp. 25–36, 2010.
[18] A. A. Abbass, “Intensive short-term dynamic psychotherapy of
treatment-resistant depression: a pilot study,” Depression and
Anxiety, vol. 23, no. 7, pp. 449–452, 2006.
[19] C. Bressi, M. Porcellana, P. M. Marinaccio, E. P. Nocito, and
L. Magri, “Short-term psychodynamic psychotherapy versus
treatment as usual for depressive and anxiety disorders: a
randomizedclinicaltrialofeﬃcacy,”eJournalofNervousand
Mental Disease, vol. 198, no. 9, pp. 647–652, 2010.
[20] M. J. Hilsenroth, S. J. Ackerman, M. D. Blagys, M. R. Baity, and
M. A. Mooney, “Short-term psychodynamic psychotherapy for
depression: an examination of statistical, clinically signi�cant,
and techni�ue-speci�c change,” e Journal of Nervous and
Mental Disease, vol. 191, no. 6, pp. 349–357, 2003.
[21] J. Wålinder and W. Rutz, “Male depression and suicide,”
International Clinical Psychopharmacology, vol. 16, supplement
2, pp. S21–S24, 2001.
[22] W. Rutz, “Improvement of care for people suﬀering from
depression: the need for comprehensive education,” Interna-
tional Clinical Psychopharmacology, vol. 14, supplement 3, pp.
S27–S33, 1999.
[23] A. M. Moller-Leimkuhler and M. Yucel, “Male depression in
females?” Journal of Aﬀective Disorders, vol. 121, no. 1, pp.
22–29, 2010.
[24] A. Rihmer, S. Szilagyi, S. Rozsa et al., “e role of childhood
abuse in adult suicidal behaviour,” Neuropsychopharmacologia
Hungarica, vol. 11, no. 4, pp. 237–246, 2009.
[25] M. Pompili, M. Innamorati, D. Lester et al., “Substance abuse,
temperament and suicide risk: evidence from a case-control
study,” Journal of Addictive Diseases, vol. 28, no. 1, pp. 13–20,
2009.
[26] M. Hamilton, “A rating scale for depression,” Journal of Neurol-
ogy, Neurosurgery, and Psychiatry, vol. 23, pp. 56–62, 1960.
[27] D. V. Sheehan, Y. Lecrubier, K. H. Sheehan et al., “e Mini-
International Neuropsychiatric Interview (M.I.N.I.): the devel-
opment and validation of a structured diagnostic psychiatric
interview for DSM-IV and ICD-10,” e Journal of Clinical
Psychiatry, vol. 59, supplement 20, pp. 22–33, 1998.
[28] A. T. Beck, A. Weissman, D. Lester, and L. Trexler, “e
measurement of pessimism: the hopelessness scale,” Journal of
Consulting and Clinical Psychology, vol. 42, no. 6, pp. 861–865,
1974.
[29] W. Rutz, L. von Knorring, H. Pihlgren, Z. Rihmer, and J.
Walinder, “Prevention of male suicides: lessons from Gotland
study,” e Lancet, vol. 345, no. 8948, p. 524, 1995.
[30] R. Strmberg, L. G. Backlund, and M. Lfvander, “A comparison
betweentheBeck’sDepressionInventoryandtheGotlandMale
Depression Scale in detecting depression among men visiting a
drop-inclinicinprimarycare,”NordicJournalofPsychiatry,vol.
64, no. 4, pp. 258–264, 2010.
[31] F. Zierau, A. Bille, W. Rutz, and P. Bech, “e Gotland Male
Depression Scale: a validity study in patients with alcohol
use disorder,” Nordic Journal of Psychiatry,v o l .5 6 ,n o .4 ,p p .
265–271, 2002.
[32] M. Innamorati, Z. Rihmer, M. Amore et al., “Psychometric
properties of the Gotland Scale for Depression in Italian
psychiatric inpatients and its utility in the prediction of suicide
risk,” JournalofAﬀectiveDisorders,vol.132,no.1-2,pp.99–103,
2011.
[33] A. T. Beck, G. Brown, R. J. Berchick, B. L. Stewart, and R. A.
Steer,“Relationshipbetweenhopelessnessandultimatesuicide:
a replication with psychiatric outpatients,” American Journal of
Psychiatry, vol. 147, no. 2, pp. 190–195, 1990.
[34] M. Pompili, P. Iliceto, D. Lester et al., BHS Beck Hopelessness
Scale: Manuale, Giunti O.S. Organizzazioni Speciali, Firenze,
Italy, 2009.
[35] M. Pompili, R. Tatarelli, J. R. Rogers, and D. Lester, “e
HopelessnessScale:afactoranalysis,”PsychologicalReports,vol.
100, no. 2, pp. 375–378, 2007.
[36] D. H. Malan, Toward the Validation of Dynamic Psychotherapy:
A Replication, Plenum Medical Book Co., New York, NY, USA,
1976.
[37] D. H. Malan and F. Osimo, Psychodynamics, Training, and Out-
come in Brief Psychotherapy, Butterworth-Heinemann, Boston,
Mass, USA, 1992.
[38] J. Shedler, “e eﬃcacy of psychodynamic psychotherapy,” e
American Psychologist, vol. 65, no. 2, pp. 98–109, 2010.
[39] M.M.Linehan,H.L.Heard,andH.E.Armstrong,“Naturalistic
follow-upofabehavioraltreatmentforchronicallyparasuicidal
borderline patients,” Archives of General Psychiatry,v o l .5 0 ,n o .
12, pp. 971–974, 1993.
[40] A .T .B e c ka n dR .A .S t e e r ,Beck Hopelessness Scale—Manual,
Harcourt Brace Javanovich, San Antonio, Tex, USA, 1988.
[41] H. D. Davanloo, Basic Principles and Techiniques in the Short-
Term Dynamic Psychotherapy, Spectrum, New York, NY, USA,
1978.
[42] H. D. Davanloo, Selcted Papers, Wiley, New York, NY, USA,
1990.
[43] F. Leichsenring, S. Rabung, and E. Leibing, “e eﬃcacy of
short-term psychodynamic psychotherapy in speci�c psychi-
atric disorders: a meta-analysis,” Archives of General Psychiatry,
vol. 61, no. 12, pp. 1208–1216, 2004.
[44] M. Trujillo, “Intensive dynamic psychotherapy of anxiety and
depression,” Primary Psychiatry, vol. 13, no. 5, pp. 77–86, 2006.
[45] P. Crits-Christoph, “e eﬃcacy of brief dynamic psychother-
apy: a meta-analysis,” e American Journal of Psychiatry, vol.
149, no. 2, pp. 151–158, 1992.